Ultraviolet A Is AnEfficient Therapy For Plane Warts

Background:Treatment ofplane warts presents a special therapeutic problem because their duration is long, and very resistant to many treatments. In addition they are usually located in cosmetically important areas, so therapy should be as mild as possible, and potential scarring should be avoided. Ultraviolet a radiation refers to electromagnetic radiation with wavelength (320-400nm) which penetrate deeper into dermal structures' and carry less energy when compare to UVB. Objective:To evaluate the efficacy and safety of ultraviolet A in the treatment of plane warts. Patients and Methods:Open therapeutic study was conducted indepartment of Dermatology, In Baquba Teaching Hospital,Diyala health directorate.A total of 60 patients with plane warts aged from 4 to 29 yearswere enrolled in the study between June 2015  to May 2016,all treated with ultraviolet A light,the treatment continue for 3 sessions/week (every other day) for 4 weeks. Results: Six patients were healed two weeks from starting of treatment, 35 patients were healed after completion of treatment(4 weeks),four patients healed four weeks after stopping of treatment,15 patient showed no response to UVA in treatment of plane warts.no significant side effects observed other than transient erythema and postinflammatorypigmentary changes. Conclusion: We conclude that UVA is effective and safe modality treatment for recalcitrant plane warts

A newly developed strain of Enterococcus faecium isolated from fresh dairy products to be used as a probiotic in lactating Holstein cows

The objective of this study was to determine the ability of an isolated strain (EGY_NRC1) or commercial (NCIMB 11181) Enterococcus faecium as a probiotic for lactating cows. Two experiments were conducted: In Experiment 1, the effects of three levels (1, 2, and 3 g/kg diet, DM basis) of isolated and commercial E. faecium on in vitro ruminal fermentation kinetics, gas, methane (CH4) and nutrient degradability were determined. In Experiment 2, thirty multiparous Holstein cows (633 ± 25.4 kg body weight) with 7 days in milk, were randomly assigned to 3 treatments in a completely randomized design in a 60-day experiment. Cows were fed without any additives (control treatment) or supplemented with 2 g/kg feed daily of E. faecium EGY_NRC1 (contain 1.1 × 109 CFU/g) or commercial E. faecium NCIMB 11181 (contain 2 × 1012 CFU/g). Diets were prepared to meet cow's nutrient requirements according to NRC recommendations. Probiotic doses were based on the in vitro Experiment 1. Feed intake, digestibility, blood parameters and lactation performance were evaluated. In Experiment 1, the isolated E. faecium linearly and quadratically increased (P < 0.001) in vitro total gas production (TGP), the degradability of dry matter (dDM) and organic matter (dOM) while decreased (P < 0.05) methane (CH4) percent of TGP, NH3CH4 production, and pH. The commercial E. faecium increased TGP and decreased (P < 0.01) CH4 production, pH and increased the dDM and dOM, short chain fatty acids and ruminal NH3-N concentration. In Experiment 2, the isolated E. faecium increased (P < 0.01) total tract digestibility of DM, neutral and acid detergent fiber, daily milk production and feed efficiency compared to the control treatment without affecting feed intake and milk composition. Moreover, the isolated E. faecium increased (P < 0.05) the proportion of C18:1 trans-9, C18:2 cis-9-12 and C18:2 trans-10 cis-12. Both isolated and commercial E. faecium improved (P < 0.01) organic matter, crude protein and nonstructural carbohydrates digestibility, increased serum glucose (P = 0.002) and decreased serum cholesterol (P = 0.002). Additionally, both E. faecium strains decreased C23:0 (P = 0.005) in milk. In conclusion, the use of E. faecium (isolated and commercial) at 2 g/kg DM of feed improved feed efficiency and production performance, with superior effects on animal performance from isolated E. faecium compared to the commercial one

A mini review on the development of conjugated polymers: steps towards the commercialization of organic solar cells

This review article covers the synthesis and design of conjugated polymers for carefully adjusting energy levels and energy band gap (EBG) to achieve the desired photovoltaic performance. The formation of bonds and the delocalization of electrons over conjugated chains are both explained by the molecular orbital theory (MOT). The intrinsic characteristics that classify conjugated polymers as semiconducting materials come from the EBG of organic molecules. A quinoid mesomeric structure (D-A ↔ D+ = A−) forms across the major backbones of the polymer as a result of alternating donor–acceptor segments contributing to the pull–push driving force between neighboring units, resulting in a smaller optical EBG. Furthermore, one of the most crucial factors in achieving excellent performance of the polymer is improving the morphology of the active layer. In order to improve exciton diffusion, dissociation, and charge transport, the nanoscale morphology ensures nanometer phase separation between donor and acceptor components in the active layer. It was demonstrated that because of the exciton’s short lifetime, only small diffusion distances (10–20 nm) are needed for all photo-generated excitons to reach the interfacial region where they can separate into free charge carriers. There is a comprehensive explanation of the architecture of organic solar cells using single layer, bilayer, and bulk heterojunction (BHJ) devices. The short circuit current density (Jsc), open circuit voltage (Voc), and fill factor (FF) all have a significant impact on the performance of organic solar cells (OSCs). Since the BHJ concept was first proposed, significant advancement and quick configuration development of these devices have been accomplished. Due to their ability to combine great optical and electronic properties with strong thermal and chemical stability, conjugated polymers are unique semiconducting materials that are used in a wide range of applications. According to the fundamental operating theories of OSCs, unlike inorganic semiconductors such as silicon solar cells, organic photovoltaic devices are unable to produce free carrier charges (holes and electrons). To overcome the Coulombic attraction and separate the excitons into free charges in the interfacial region, organic semiconductors require an additional thermodynamic driving force. From the molecular engineering of conjugated polymers, it was discovered that the most crucial obstacles to achieving the most desirable properties are the design and synthesis of conjugated polymers toward optimal p-type materials. Along with plastic solar cells (PSCs), these materials have extended to a number of different applications such as light-emitting diodes (LEDs) and field-effect transistors (FETs). Additionally, the topics of fluorene and carbazole as donor units in conjugated polymers are covered. The Stille, Suzuki, and Sonogashira coupling reactions widely used to synthesize alternating D–A copolymers are also presented. Moreover, conjugated polymers based on anthracene that can be used in solar cells are covered

Lactation performance and feed utilization of Rahmani ewes fed with either a newly produced bacteriocin-like substance or a commercial bacteriocin

The aim of the present study was to compare the effect of feeding a newly produced bacteriocin-like substance from Lactococcus lactis ssp. lactis (PNP) with a commercial bacteriocin (NISEEN-S; CNP) in lactating Rahmani ewe diets. In experiment 1, the effects of four levels (500, 1,000, 1,500, and 2,000 unit/kg substrate, dry matter (DM) basis) of both bacteriocins on in vitro ruminal fermentation kinetics, total gas production (TGP), methane production (CH4), and nutrient degradability were determined. In experiment 2, 2 wk before the expected parturition, 30 multiparous lactating Rahmani ewes (mean ± SD: 2 ± 0.3 parity, 46.8 ± 2.5 kg body weight, 23 ± 2.7 mo of age, and 370 ± 13 g/d of previous milk production) were equally divided into three treatments in a complete randomized design for 90 d. The ewes in the control treatment were offered a diet composed of 600 g of concentrate feed mixture, 300 g berseem hay, and 100 g of faba bean straw (Control), or supplemented with produced bacteriocin like substance (PNP) or commercial (CNP) bacteriocin at 500 unit/kg feed (DM basis). In experiment 1, both PNP and CNP linearly and quadratically decreased (P < 0.001) CH4 production; however, PNP and CNP at 500 unit/kg feed quadratically increased fiber degradability (P < 0.01). In experiment 2, both PNP and CNP increased (P < 0.05) nutrient digestibility, and ruminal total volatile fatty acids, acetate, and propionate, while decreasing ruminal ammonia-N. The PNP treatment increased (P < 0.05) blood total proteins and albumin, while PNP and CNP treatments increase serum glucose. Both PNP and CNP treatments increased (P < 0.05) daily milk production and milk efficiency, without affecting the concentration of milk components. Both PNP and CNP are recommended to improve feed utilization and milk production, with superior results detected for PNP at 500 unit/kg feed daily

The Functions of Mediator in Candida albicans Support a Role in Shaping Species-Specific Gene Expression

The Mediator complex is an essential co-regulator of RNA polymerase II that is conserved throughout eukaryotes. Here we present the first study of Mediator in the pathogenic fungus Candida albicans. We focused on the Middle domain subunit Med31, the Head domain subunit Med20, and Srb9/Med13 from the Kinase domain. The C. albicans Mediator shares some roles with model yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe, such as functions in the response to certain stresses and the role of Med31 in the expression of genes regulated by the activator Ace2. The C. albicans Mediator also has additional roles in the transcription of genes associated with virulence, for example genes related to morphogenesis and gene families enriched in pathogens, such as the ALS adhesins. Consistently, Med31, Med20, and Srb9/Med13 contribute to key virulence attributes of C. albicans, filamentation, and biofilm formation; and ALS1 is a biologically relevant target of Med31 for development of biofilms. Furthermore, Med31 affects virulence of C. albicans in the worm infection model. We present evidence that the roles of Med31 and Srb9/Med13 in the expression of the genes encoding cell wall adhesins are different between S. cerevisiae and C. albicans: they are repressors of the FLO genes in S. cerevisiae and are activators of the ALS genes in C. albicans. This suggests that Mediator subunits regulate adhesion in a distinct manner between these two distantly related fungal species

Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study

Background Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide.Methods A multimethods analysis was performed as part of the GlobalSurg 3 study-a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital.Findings Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3.85 [95% CI 2.58-5.75]; p&lt;0.0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63.0% vs 82.7%; OR 0.35 [0.23-0.53]; p&lt;0.0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer.Interpretation Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Background: Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. // Methods: We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung's disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. // Findings: We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung's disease) from 264 hospitals (89 in high-income countries, 166 in middle-income countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in low-income countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. // Interpretation: Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between low-income, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030